News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
This transaction is the third acquisition by three different Japanese players in this segment
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Shares and American Depositary Shares of Olink for $26.00 per Share
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Subscribe To Our Newsletter & Stay Updated
